Pfanstiehl Announces New Histidine Products for Biopharmaceutical Formulations
Suitable for bioprocessing, solubilization, and stabilization applications, the new histidine products allow for the control of endotoxin and trace metal impurities reflected with elemental impurity data in parts per billion on their specifications.
Pfanstiehl announced that it has launched high purity, low endotoxin, low metal L-histidine and L-histidine hydrochloride monohydrate for a new quality standard for amino acids.
Suitable for bioprocessing, solubilization, and stabilization applications, the new histidine products allow for the control of endotoxin and trace metal impurities reflected with elemental impurity data in parts per billion on their specifications, a June 25, 2020 company press release said. The products are now available for customer qualification and manufacturing, product profiles, and regulatory documentation.
“Pfanstiehl’s amino acid specifications exceed regulatory requirements and reflect our leadership in setting high quality industry standards for the biopharma market,” said Chandra Kelley, director of business development, Pfanstiehl, in the press release.
Source: Pfanstiehl
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
